文献速递脑血管病神经重症与神经感染

心房颤动合并隐匿性脑梗死患者缺血性卒中后早期与晚期抗凝治疗的比较

Early vs Late Anticoagulation After Ischemic Stroke in Patients With Atrial Fibrillation and Covert Brain Infarcts.
PubMed 文献 · Neurology · 2024-12-19

该研究为ELAN试验的事后分析,纳入1694例首次缺血性卒中合并心房颤动患者,其中678例(40.0%)存在隐匿性脑梗死。在隐匿性脑梗死患者中,早期直接口服抗凝药组主要结局发生率为2.3%,晚期组为6.0%,校正风险差为-3.6%(95%CI -6.6至-0.6),交互作用P值为0.063。

要点

  • 隐匿性脑梗死患者中,早期直接口服抗凝药与较低的主要结局风险相关(校正风险差-3.6%,95%CI -6.6至-0.6)。
  • 早期治疗组未观察到症状性颅内出血。
  • 隐匿性脑梗死患者早期治疗复发性缺血性卒中风险较低(校正风险差-2.7%,95%CI -5.0至-0.4)。

核心结论

  • 隐匿性脑梗死可能提示首次缺血性卒中合并心房颤动患者中从早期直接口服抗凝药启动中获益的亚组,可预防缺血事件复发且不增加伤害。
  • 研究结果为卒中合并心房颤动患者及时直接口服抗凝药治疗的临床决策提供参考。

研究设计与样本

  • 国际、多中心、随机对照ELAN试验的事后分析。
  • 比较早期(轻型及中型卒中<48小时,重型卒中6-7天)与晚期(轻型>48小时,中型3-4天,重型12-14天)启动直接口服抗凝药。
  • 纳入1694例首次缺血性卒中合并心房颤动患者,中位年龄77岁,女性占45.9%。

主要发现

  • 678例(40.0%)存在隐匿性脑梗死,影像核心实验室评定者间信度为0.87(0.81-0.94)。
  • 隐匿性脑梗死患者中,早期组主要结局发生8例(2.3%;复发性缺血性卒中3/342),晚期组发生20例(6.0%;复发性缺血性卒中12/336),校正风险差-3.6%(95%CI -6.6至-0.6),交互作用P=0.063。
  • 早期直接口服抗凝药治疗下,隐匿性脑梗死患者复发性缺血性卒中风险较低(校正风险差-2.7%,95%CI -5.0至-0.4),无隐匿性脑梗死患者未见降低(校正风险差-0.4,95%CI -2.1至1.2)。
  • 早期治疗组未观察到症状性颅内出血。

临床怎么用

  • 作者认为,隐匿性脑梗死的存在可能提示首次缺血性卒中合并心房颤动患者可从早期直接口服抗凝药启动中特别获益,以预防缺血事件复发且不增加伤害。
  • 作者认为,研究结果应在卒中合并心房颤动患者及时直接口服抗凝药治疗的临床决策中加以考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Covert brain infarcts (CBIs) in patients with first-ever ischemic stroke (IS) and atrial fibrillation (AF) are associated with an increased risk of stroke recurrence. We aimed to assess whether CBIs modify the treatment effect of early vs late initiation of direct oral anticoagulants (DOACs) in patients with IS and AF. METHODS: We conducted a post hoc analysis of the international, multicenter, randomized-controlled ELAN trial, which compared early (<48 hours after ischemic stroke for minor and moderate stroke, 6-7 days for major stroke) vs late (>48 hours for minor, 3-4 days for moderate, 12-14 days for major stroke) initiation of DOACs in patients with IS and AF. The primary outcome was a composite of recurrent IS, symptomatic intracranial hemorrhage (sICH), major extracranial bleeding, systemic embolism, or vascular death within 30 days after stroke; secondary outcomes were the individual components. We estimated outcomes based on the presence of CBIs (any CBI vs no CBI) on prerandomization imaging (core-lab rating) using adjusted risk differences (aRDs) between treatment arms. Point estimates and 95% CIs are presented without reporting p values. RESULTS: Of the 1,694 participants with first-ever IS included (median age: 77 years, 45.9% female), 678 (40.0%) had CBI. The imaging core-lab interrater reliability for the presence of CBI was 0.87 (0.81-0.94). The primary outcome occurred in 8 (2.3%; recurrent IS: 3/342) of 342 participants with CBI assigned to the early treatment arm vs 20 (6.0%; recurrent IS: 12/336) of 336 assigned to the late treatment arm (aRD: -3.6%, 95% CI -6.6 to -0.6) (p for interaction: 0.063). With early DOAC treatment, IS recurrence risk was lower in participants with CBI (aRD: -2.7%, 95% CI -5.0 to -0.4), but not in participants without CBI (aRD: -0.4, 95% CI -2.1 to 1.2). No sICH was observed in the early treatment group. DISCUSSION: The presence of CBI may indicate a subgroup of patients with first-ever IS and AF who particularly benefits from early DOAC initiation to prevent ischemic event recurrence, without increasing harm. Our findings should be considered in clinical decision making regarding timely DOAC treatment in patients with stroke and AF. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in patients with covert brain infarcts, atrial fibrillation, and first-ever ischemic stroke, early (vs late) initiation of DOACs is associated with lower risk of recurrent stroke with no increase in harm. TRIAL REGISTRATION INFORMATION: URL: clinicaltrials.gov/study/NCT03148457; Unique identifier: NCT03148457; submitted: April 7, 2017; first patient enrolled: November 6, 2017.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kneihsl M, Hakim A, Goeldlin MB, et al. Early vs Late Anticoagulation After Ischemic Stroke in Patients With Atrial Fibrillation and Covert Brain Infarcts. Neurology. 2024. PMID: 39700448. doi:10.1212/WNL.0000000000210157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。